Piper Sandler Starts Immunovant (IMVT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMVT Hot Sheet
Price: $29.90 +2.96%
Rating Summary:
16 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
16 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Immunovant (NASDAQ: IMVT) with a Overweight rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.
Shares of Immunovant closed at $15.47 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Freedom Broker Starts Lamb Weston (LW) at Hold
- Citi Starts TCL Electronics Holdings (1070:HK) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
